55876-91-0

Basic information

• Product Name: METHYL 5-FORMYLPICOLINATE
• Synonyms: METHYL 5-FORMYLPICOLINATE;ethyl 5-forMylpicolinate;5-ForMyl-pyridine-2-carboxylic acid Methyl ester;methyl 5-formylpyridine-2-carboxylate;2-Pyridinecarboxylic acid, 5-formyl-, methyl ester;5-formyl-2-Pyridinecarboxylic acid methyl ester
• CAS NO: 55876-91-0
• Molecular Formula: C₈H₇NO₃
• Molecular Weight: 165.15
• Mol File: 55876-91-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 322.7°C at 760 mmHg
• Flash Point: 148.9°C
• Appearance: /
• Density: 1.249g/cm³
• Vapor Pressure: 0.000275mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.11±0.10(Predicted)
• CAS DataBase Reference: METHYL 5-FORMYLPICOLINATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 5-FORMYLPICOLINATE(55876-91-0)
• EPA Substance Registry System: METHYL 5-FORMYLPICOLINATE(55876-91-0)

Safety Data

• Hazardous Substances Data: 55876-91-0(Hazardous Substances Data)

Usage

General Description

Methyl 5-formylpicolinate is an organic compound with the molecular formula C8H7NO3. It is a formylated derivative of picolinic acid, a heterocyclic aromatic carboxylic acid. Methyl 5-formylpicolinate is commonly used as a building block in organic synthesis, particularly in the pharmaceutical industry. It is also used in the synthesis of various chemical compounds, including potential drug candidates and agrochemicals. Methyl 5-formylpicolinate has potential applications in medicinal chemistry and drug discovery due to its versatile chemical properties and structural features. Additionally, it can serve as a valuable reagent in the preparation of complex organic molecules for research and industrial purposes.

InChI:InChI=1/C8H7NO3/c1-12-8(11)7-3-2-6(5-10)4-9-7/h2-5H,1H3

Upstream product

• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 149806-06-4 6-bromonicotinaldehyde 

Downstream Products

• 1239173-97-7 C₂₁H₁₈F₃N₃O₅ 

Relevant articles and documents

COMPOUNDS AND METHODS OF USE

This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.

LSD1 INHIBITORS AND USES THEREOF

Provided are novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSDl. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSDl.

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.